Esophageal Cancer
Copyright ©2005 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 28, 2005; 11(16): 2385-2389
Published online Apr 28, 2005. doi: 10.3748/wjg.v11.i16.2385
No association of the matrix metalloproteinase 1 promoter polymorphism with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in northern China
Xia Jin, Gang Kuang, Li-Zhen Wei, Yan Li, Rui Wang, Wei Guo, Na Wang, Shu-Mei Fang, Deng-Gui Wen, Zhi-Feng Chen, Jian-Hui Zhang
Xia Jin, Gang Kuang, Li-Zhen Wei, Yan Li, Wei Guo, Na Wang, Deng-Gui Wen, Zhi-Feng Chen, Shu-Mei Fang, Jian-Hui Zhang, Hebei Cancer Institute, Hebei Medical University, Shijiazhuang 050011, Hebei Province, China
Rui Wang, The Fourth Affiliated Hospital, Hebei Medical University, Shijiazhuang 050011, Hebei Province, China
Author contributions: All authors contributed equally to the work.
Supported by the Grant from the Natural Science Foundation of China, No. 30371591, and Grant from Natural Science Foundation of Hebei Province, China, No. C200400062
Correspondence to: Professor Jian-Hui Zhang, Hebei Cancer Institute, Hebei Medical University, Jiankanglu 12, Shijiazhuang 050011, Hebei Province, China. jianhuizh@hotmail.com
Telephone: +86-311-6093338 Fax: +86-311-6077634
Received: March 20, 2004
Revised: March 21, 2004
Accepted: April 14, 2004
Published online: April 28, 2005
Abstract

AIM: To investigate association of the 2G or1G single nucleotide polymorphism (SNP) in matrix metalloproteinase 1 (MMP1) promoter with susceptibility to esophageal squam-ous cell carcinoma (ESCC) and gastric cardiac adenocarcinoma (GCA) in a population of North China.

METHODS: MMP1 promoter SNP was genotyped by polymerase-chain reaction (PCR)-restriction fragment length polymorphism (RFLP) analysis in 417 cancer patients (234 ESCC and 183 GCA) and 350 healthy controls.

RESULTS: The genotype frequencies of the MMP1 promoter SNP in healthy controls were 55.4% (2G/2G), 30% (1G/2G) and 14.6% (1G/1G), respectively. The genotype and allelotype distribution in ESCC and GCA patients was not significantly different from that in healthy controls (all P values were above 0.05). Compared with the 1G/1G genotype, neither the 2G/2G nor in combination with the 1G/2G genotype significantly modified the risk of developing ESCC and GCA, the adjusted odds ratio was 1.28 (95%CI = 0.78-2.09), 1.23 (95%CI = 0.38-2.05) in ESCC and 1.39 (95%CI = 0.80-2.41), 1.34 (95%CI = 0.74-2.40) in GCA, respectively. When stratified by smoking status and family history of upper gastrointestinal cancer, the 2G/2G genotype alone or in combination with the 1G/2G genotype also did not show any significant influence on the risk of ESCC and GCA development. In addition, influence of the MMP1 SNP on lymphatic metastasis in ESCC and GCA was also not obs-erved.

CONCLUSION: The 2G or 1G SNP in the MMP1 promoter might not modify the risk of ESCC and GCA development and might not be used as a stratification marker to predict the potential of lymphatic metastasis in these two tumor types.

Keywords: SNP; ESCC; GCA